EID2

Across TCGA pan-cancer cohorts, EID2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EID2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher EID2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EID2 expression acts as an unfavorable survival marker.

KIRC, COAD, and LUAD are the cancer types where EID2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.133	0.805	<.001	42	view →
COAD	DFS	Median	All	0.140	0.783	<.001	18	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EID2–KIRC (OS)

Open the KIRC breakdown →